Skip to main content

SWEDISH ORPHAN BIOVITRUM Value Stock - Dividend - Research Selection

Swedish Orphan Biovitrum AB

ISIN: SE0000872095, WKN: A0LA5K

Market price date: 26.01.2022
Market price: 179,55 SEK


Swedish Orphan Biovitrum AB Fundamental data and company key figures of the share

Annual reports in SEK
Key figures 28-09-2021
Cash flow
Net operating cash flow 5.214.000.000
Capital Expenditures -41.000.000
Free cash flow 5.173.000.192
Balance sheet
Total Equity 20.206.000.000
Liabilities & Shareholders equity 48.283.000.000
Income statement
Net income 3.245.000.000
Eps (diluted) 11,004
Diluted shares outstanding 294.897.000
Net sales/revenue 15.261.000.000

Fundamental ratios calculated on: 26-01-2022

Ratios
Key figures 26-01-2022
Cash flow
P/C 10,16
   
P/FC 10,24
Balance sheet
ROI6,72
ROE41,85
Income statement
P/E16,32
Div. Yield0,00%
P/B2,62
P/S3,47


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSOBI.ST
Market Capitalization5.970.968.576,00 USD
CountrySweden
IndicesSTOXX EUROPE 600
SectorsBiotechnology
Raw Data SourceIFRS in Millionen SEK
Stock Split2011-05-03,1265.000000/1132.000000; 2009-12-07,717.000000/359.000000
Internetwww.sobi.com


Description of the company

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.sobi.com


NEWS